Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Medicaid Work Mandate
  • Suicide Prevention
  • Community Health Workers
  • Rural Health Payout
  • Opioid Crisis

TRENDING TOPICS:

  • Medicaid Work Mandate
  • Suicide Prevention
  • Community Health Workers
  • Rural Health Payout
  • Opioid Crisis

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Tuesday, Nov 24 2020

Full Issue

Viewpoints: Not Protecting Workers From COVID Is Bad Health Policy; Patience To All On Vaccines' Arrivals

Editorial pages focus on these pandemic topics and other public health issues.

Stat: 'Absurd Reinterpretation' Of OSHA Rule About Workers And Covid-19 

Workplace exposures continue to be a major driver of the coronavirus pandemic, something that the Occupational Safety and Health Administration (OSHA) should be on top of. But a reinterpretation of a reporting rule is making that all but impossible. (David Michaels, 11/24)

The Washington Post: Vaccines Are Coming. Fasten Your Seat Belts, And Be Patient.

The vaccines are coming, and the prospect of several effective inoculations to combat the coronavirus pandemic is a remarkable scientific achievement. But even in the best of conditions, it will take time to overcome manufacturing and logistics hurdles, and to distribute hundreds of millions of shots equitably. Fasten your seat belts, and be patient. (11/23)

Bloomberg: Vaccine Distribution Shouldn’t Be Fair

As an increasing body of evidence suggests America’s new anti-Covid vaccines are both efficacious and safe, the question of how to distribute those vaccines assumes greater importance. One poll suggests that Americans think health-care workers, the elderly and people with compromised immune systems should receive vaccines very early. But what to do after that? There is an uncomfortable truth here: Most of the best distribution methods are blatantly unfair. In this context, however, fairness is overrated. Priority should be given to methods that will save more lives and bring back the economy more rapidly. (Tyler Cowen, 11/23)

Stat: Neglected Tropical Diseases Should Get Covid-19-Like Innovation

With the first results of multiple Covid-19 vaccine candidates giving hope to billions of people around the world, the power of biomedical research has captured the public’s attention. The speed with which it moved to develop vaccines, treatments, and diagnostic tests has been impressive — although equitable access to these innovations is still unsure. (Nathalie Strub-Wourgaft, 11/24)

Bloomberg: Pricey Covid-19 Vaccines Could Spark Backlash To Patent Rights

The world is unequal enough and the Covid-19 pandemic threatens to make things more unequal still. Poorer countries have had to take on debt they will struggle to pay back. Their more fragile healthcare systems and crowded cities forced them into stricter and more economically harmful lockdowns, and poverty rates have risen dramatically. Now, they rightly fear a staggered recovery from the pandemic will further disadvantage them, given how expensive vaccine rollouts look to be. It should not be surprising then that several developing countries, led by India and South Africa, argued last week at the World Trade Organization’s intellectual property rights council that IPR-related payments should be suspended for the duration of the pandemic for Covid-19 related vaccines, therapeutics and equipment. They worry about “intellectual property rights hindering or potentially hindering timely provisioning of affordable medical products” to their citizens. (Mark Sharma, 11/23)

The Wall Street Journal: Hospitals Prepare For The New Covid Wave

The numbers across the U.S. are staggering: more than 167,000 new Covid-19 cases and 1,400 deaths a day, with more than 83,000 Americans currently hospitalized. A fall Covid surge is under way, reminiscent of the fall of 1918, which saw the second wave of the much deadlier Spanish flu. Without an intervening factor, biology, like history, repeats itself. New York is battling a rising disease prevalence but has so far escaped a second significant spike. No doubt a tough fall and winter lie ahead, with the virus spreading, pandemic fatigue growing, and cold weather sending people indoors to socialize. (Mark Jarrett and Bruce Farber, 11/23)

The Hill: Protect Our World: How The Biden Administration Can Save Lives And Economies Worldwide 

At Joe Biden takes his oath to become the 46th president of the United States, the U.S. should learn three important lessons. Infectious diseases can ambush advanced and developing economies alike; preventing them may create even more wealth than we had thought. What looks like a pocket or a local outbreak can turn into a threat to global wellbeing in as little time as it takes a 787 to fly from one side of the world to the other. Sharing the responsibility for preventing this spread of infections serves American and global interests. (Amanda Glassman, 11/23)

Los Angeles Times: Our 'America First' President Outsourced Drug Price Regulation To Other Nations 

President Trump has largely been a corrosive force on healthcare issues, working to undermine the Affordable Care Act and advancing policies that favored younger, healthier people at the expense of Americans with preexisting conditions. But on prescription drugs — an area largely overlooked by the ACA — he’s aligned himself with the millions of consumers deeply concerned about the cost of new or specialty drugs. The Trump administration responded to that concern in its most concrete way yet on Friday, announcing a pair of controversial steps that could ultimately save money for taxpayers and many consumers. (11/24)

The Hill: Job Number Two For The FDA: Reducing Salt

It is crystal clear that job number one for the U.S. Food and Drug Administration (FDA) is helping tackle the coronavirus pandemic. However, that doesn’t mean that the FDA, particularly its Center for Food Safety and Applied Nutrition, should ignore other major causes of rampant illness and death. We’re thinking of salt. Yes, salt, innocent crystals of which are in half of all packaged foods and practically every factory, restaurant and kitchen in America. (Michael F. Jacobson and Marsha N. Cohen, 11/23)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Wednesday, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF